Showing results (871-880 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|April 8, 2010
SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2Barrie Peck, Chun-Yuan Chen, Ka-Kei Ho, et al.
Molecular Cancer Therapeutics|April 8, 2010
Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800Andrew J Massey, Joseph Schoepfer, Paul A Brough, et al.
Molecular Cancer Therapeutics|April 8, 2010
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanomaChristina K Augustine, Sin-Ho Jung, Insuk Sohn, et al.
Molecular Cancer Therapeutics|April 8, 2010
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myelomaDiana Cirstea, Teru Hideshima, Scott Rodig, et al.
Molecular Cancer Therapeutics|April 8, 2010
RelB-dependent differential radiosensitization effect of STI571 on prostate cancer cellsYong Xu, Fang Fang, Yulan Sun, et al.
Molecular Cancer Therapeutics|April 1, 2010
beta-Ionone enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells through Sp1-dependent upregulation of DR5 and downregulation of NF-kappaB activityMun-Ock Kim, Dong-Oh Moon, Chang-Hee Kang, et al.
Molecular Cancer Therapeutics|April 1, 2010
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapyJitesh P Jani, Joel Arcari, Vincent Bernardo, et al.
Molecular Cancer Therapeutics|May 12, 2010
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expressionMichael S Bobola, Douglas D Kolstoe, A Blank, et al.
Molecular Cancer Therapeutics|June 10, 2010
High-content phenotypic profiling of drug response signatures across distinct cancer cellsPeter D Caie, Rebecca E Walls, Alexandra Ingleston-Orme, et al.
Molecular Cancer Therapeutics|June 11, 2009
Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancerJohn S P Yuen, Erdem Akkaya, Yong Wang, et al.
Pageof 599